IDEAS home Printed from https://ideas.repec.org/a/epw/clinic/v6y2025i2id12367.html

Triple Negative Breast Cancer (TNBC) Prognostic Value of Micro RNA-454 Expression for Overall Survival

Author

Listed:
  • Dita Ria Selvyana

    (Muhammadiyah Yogyakarta University, Indonesia)

  • Ibnu Purwanto

    (Dr. Sardjito Hospital, Indonesia)

  • Mardiah Suci Hardianti

    (Dr. Sardjito Hospital, Indonesia)

Abstract

Breast cancer is the most common type of cancer and the primary cause of death among women who have been diagnosed with cancer. Luminal A, Luminal B, HER2/neu+, and Triple Negative Breast Cancer are the four subtypes that are used to classify breast cancer. Currently, there is no specific targeted therapy for triple-negative breast cancer (TNBC), resulting in a brief median recurrence time and unfavorable prognosis. Recent studies have demonstrated that miRNA-454 plays an oncogenic role in several different malignancies, and this role is associated with the growth, invasion, and metastasis of tumors. We analyzed miRNA-454 expression in 50 paraffin-embedded tissue samples from TNBC patients at Dr. Sardjito Hospital Yogyakarta utilizing qRT-PCR. The purpose of this research was to determine whether or not the expression of miRNA-454 is useful to forecast survival in patients with stage I-III transformational breast cancer. Methods: This investigation was a retrospective cohort study utilizing data from clinical TNBC patients at Dr. Sardjito Hospital in Yogyakarta from 2014 to 2017. Fifty patients were incorporated into the analysis. Data on clinicopathological features were documented. The results of the univariate analysis showed that patients with high miRNA-454 expression had a higher probability of dying within two years compared to those with low miRNA-454 expression (79.2% versus 53.8%; HR = 4.334; P = 0.037). Multivariate analysis indicated that elevated miRNA-454 expression heightened the 2-year mortality risk, with a hazard ratio of 3.086 (95% CI: 1.082-8.806; p=0.035). Conclusions: The expression of MiRNA 454 serves as an independent prognostic indicator for survival in patients with triple-negative breast cancer (TNBC). Patients with triple-negative breast cancer with elevated miRNA-454 expression demonstrate a reduced survival rate. The expression of miRNA-454 is also a factor that can be used to predict the therapeutic response in TNBC.

Suggested Citation

  • Dita Ria Selvyana & Ibnu Purwanto & Mardiah Suci Hardianti, 2025. "Triple Negative Breast Cancer (TNBC) Prognostic Value of Micro RNA-454 Expression for Overall Survival," European Journal of Clinical Medicine, European Open Science, vol. 6(2), pages 14-20, May.
    • Handle: RePEc:epw:clinic:v:6:y:2025:i:2:id:12367
    DOI: 10.24018/clinicmed.2025.6.2.367
    as

    Download full text from publisher

    File URL: https://eu-opensci.org/index.php/clinicmed/article/view/12367
    File Function: Abstract page
    Download Restriction: no
    File URL: https://eu-opensci.org/index.php/clinicmed/article/download/12367/2669
    File Function: Full text
    Download Restriction: no
    File URL: https://libkey.io/10.24018/clinicmed.2025.6.2.367?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Keywords

    ;
    ;
    ;

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:epw:clinic:v:6:y:2025:i:2:id:12367. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Support Team (email available below). General contact details of provider: https://eu-opensci.org/index.php/clinicmed .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.